Entrada Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Dipal Doshi
- Full Time Employees
- 152
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- One Design Center Place Boston MA United States of America 02210
- IPO Date
- Oct 29, 2021
- CIK
- 0001689375
- Website
- entradatx.com
- Similar Companies
- Business
- Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of a new class of medicines based on its proprietary Endosomal Escape Vehicle (EEV™) platform. The company focuses on enabling the intracellular delivery of therapeutics that target previously inaccessible intracellular pathways. Its core product pipeline features EEV-conjugated oligonucleotide therapeutics designed primarily for neuromuscular diseases, including Duchenne muscular dystrophy (DMD), with lead programs ENTR-601-44 and ENTR-601-45 targeting exon 44 and exon 45 skipping amenable DMD patients, respectively. The company also develops programs targeting myotonic dystrophy type 1 (ENTR-701), mitochondrial neurogastrointestinal encephalomyopathy, ocular diseases, immunology, oncology, and central nervous system disorders. These products leverage EEV technology to deliver RNA-, antibody-, and enzyme-based therapies across multiple organs and tissues. Founded in 2017 and headquartered in Boston, Massachusetts, Entrada Therapeutics operates globally with a focus on advancing its therapeutic pipeline through clinical trials and strategic partnerships. Recent major developments include authorization by regulatory authorities in the United Kingdom and the European Union to initiate Phase 1/2 multiple ascending dose clinical studies for ENTR-601-44 and ENTR-601-45, marking significant clinical advancement in the Duchenne muscular dystrophy franchise. The company has also achieved key milestones under its global collaboration with Vertex Pharmaceuticals on VX-670, a clinical-stage program for myotonic dystrophy type 1, and maintains a strategic partnership with Pierrepont Therapeutics focused on mitochondrial diseases. Collaboration revenue reached $210.8 million in 2024, reflecting these strategic alliances and clinical progress. Entrada is expanding its Duchenne franchise with additional planned filings for exon 50 targeting therapies expected to further broaden patient reach. Entrada Therapeutics is advancing robust clinical and preclinical development programs leveraging its modular EEV platform to address high unmet medical needs in rare and serious diseases. Its unique approach aims to transform treatment paradigms by delivering challenging intracellular therapies with improved efficacy and therapeutic index. The company remains focused on the development and commercialization potential of these novel therapeutics across neuromuscular, ocular, immunological, metabolic, and oncology segments, supported by a strong financial position and a growing network of strategic collaborations. This profile reflects the latest information as of late 2025, highlighting Entrada Therapeutics’ leadership in innovative intracellular drug delivery technology and its progression into clinical development phases for multiple rare diseases.
Company News
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study
Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
BlackRock Inc. Invests $19.01 Million in Entrada Therapeutics, Inc. $TRDA
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
INVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLC
TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm